March 2026 FDA Recall Bromfenac Sodium by Alembic Pharmaceuticals, Inc.
98647 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Alembic Pharmaceuticals, Inc. on March 18, 2026 for the product Bromfenac Sodium. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number:

Reason for Recall
Failed Impurities/Degradation Specifications: out of specification at the time of testing i.e. 20th month stability testing.
Initiated
03-18-2026
Reported
04-08-2026
Quantity

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
ALEMBIC PHARMACEUTICALS, INC.
Nationwide in the USA
Bromfenac Ophthalmic Solution 0.07%, 3 ml, Rx only, Sterile, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, Made in India, Manufactured by: Alembic Pharmaceuticals Limited, Karakhadi- 391 450, Gujarat, India NDC 62332-583-03.

Batch or Lot Expiration Information

Lot# 7240184, 7240185, 7240186, 7240187, Exp Date: 3/31/2026
Lot# 7240278, Exp Date: 5/31/2026.

Affected Packages Involved in this Recall